M
Michael R. Green
Researcher at University of Texas MD Anderson Cancer Center
Publications - 597
Citations - 65007
Michael R. Green is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: RNA splicing & RNA. The author has an hindex of 126, co-authored 537 publications receiving 57447 citations. Previous affiliations of Michael R. Green include Eppley Institute for Research in Cancer and Allied Diseases & United States University.
Papers
More filters
Journal ArticleDOI
Exon 9 skipping of apoptotic caspase-2 pre-mRNA is promoted by SRSF3 through interaction with exon 8.
Ha Na Jang,Minho Lee,Tiing Jen Loh,Seung Woo Choi,Hyun Kyung Oh,Heegyum Moon,Sunghee Cho,Seong Eui Hong,Do Han Kim,Zhi Sheng,Michael R. Green,Daeho Park,Xuexiu Zheng,Haihong Shen +13 more
TL;DR: It is concluded that SRSF3 promotes exon 9 skipping of caspase-2 pre-mRNA by interacting with exon 8.
Journal ArticleDOI
Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?
TL;DR: The disparate expression of IGFBP7 in BRAFV600E-positive dysplastic nevi indicates that the behavior of oncogenic BRAF in dysplastics nevi, unlike that in malignant melanoma, does not appear to consistently induce senescence/apoptosis through pathways mediated by IGF BP7.
Journal ArticleDOI
Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation.
Haopeng Yang,Michael R. Green +1 more
TL;DR: The critical importance of BCL6 and its associated epigenetic programs in the development of B-cell lymphoma is underscore, and avenues for the therapeutic targeting of B CL6 in this context are discussed.
Journal ArticleDOI
Precipitation of DNA with Isopropanol.
Michael R. Green,Joseph Sambrook +1 more
TL;DR: Preipitation with isopropanol, described here, is performed at room temperature to lessen the risk that solutes like sucrose or sodium chloride will be coprecipitated with the DNA.
Journal ArticleDOI
Selective Targeting and Inducible Destruction of Human Cancer Cells by Retroviruses with Envelope Proteins Bearing Short Peptide Ligands
TL;DR: It is demonstrated that short peptide ligands inserted at appropriate locations in MLV envelope can selectively target retroviruses to human cancer cells and deliver a therapeutically relevant gene.